CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

Changchun High-Tech Industry (Group) Co., Ltd.

000661

CNE0000007J8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 22/01/2026			5-day change	1st Jan Change
97.50 ^CNY	-0.19%		-2.60%	+5.35%

09/01	Changchun High-Tech Unit Gets Chinese Regulator's Nod for Trial of Potential Berger's Disease Drug	MT
09/01	Chinese Drug Regulator Accepts Marketing Application of Changchun High-Tech Industry's Unit for Melatonin Granules	MT

Changchun High-Tech Gets Green Light to Trial Bacterial Vaginosis Drug

Published on 11/28/2025 at 08:23 am IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Changchun High-Tech Industry (Group) Co., Ltd.

09/01	Changchun High-Tech Unit Gets Chinese Regulator's Nod for Trial of Potential Berger's Disease Drug	MT
09/01	Chinese Drug Regulator Accepts Marketing Application of Changchun High-Tech Industry's Unit for Melatonin Granules	MT
29/12	Chinese Drug Regulator Accepts Application of Changchun High-Tech's Unit for GenSci141 Ointment	MT
16/12	Changchun High-Tech Industry's Subsidiary Grants Yarrow Bioscience Worldwide Rights for Eye Disease Drug; Shares Up 4%	MT
09/12	China Includes Changchun High-Tech Industry's Growth Disorder, Anorexia Drugs in Insurance Program	MT
28/11	Changchun High-Tech Gets Green Light to Trial Bacterial Vaginosis Drug	MT
17/11	Changchun High-Tech Industry's Unit Gets Nod for GS3-007a Dry Suspension Clinical Trial; Shares Down 2%	MT
17/11	Changchun High-Tech Industry Gets Nod for GenSci140 for Injection Clinical Trial; Shares Down 2%	MT
14/11	Tranche Update on Changchun High-Tech Industry Co., Ltd.'s Equity Buyback Plan announced on November 16, 2024.	CI
14/11	Changchun High-Tech's Unit Gets US FDA's Nod for GenSci143 for Injection Clinical Trial	MT
13/11	China Approves Changchun High-Tech Industry Subsidiary's Clinical Trial for Diphtheria-Tetanus Jab	MT
13/11	Changchun High-Tech Industry Co., Ltd.'s Equity Buyback announced on November 16, 2024, has expired with 3,894,517 shares, representing 0.96% for CNY 400 million.	CI
04/11	Changchun High-Tech Unit Gets Nod For Short Stature Drug Trial	MT
03/11	Changchun High-Tech Industry Unit Gets Nod to Conduct Clinical Trials on GenSci134 Injection As Tumor Treatment	MT
03/11	Changchun High-Tech Industry's Unit Gets Nod to Conduct Clinical Trials on Growth Hormone Deficiency Drug	MT
30/25/30	Changchun High-Tech Industry Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
30/25/30	Changchun high-tech industry group Q3 net profit down 83.0% Y/Y	RE
22/25/22	Chinese Drug Administration Accepts Changchun High-Tech's Clinical Trial Application for GenSci142 Capsules	MT
21/25/21	Changchun High-Tech Industry Gets Regulatory Nod for Cancer Drug Trial	MT
20/25/20	US FDA Accepts Changchun High-Tech Industry's Application for GenSci143 Clinical Trial	MT
14/25/14	Changchun High-Tech Industry's Unit Gets Nod to Trial Influenza Vaccine; Shares Down 3%	MT
10/25/10	Changchun High-Tech Unit Gets Approval for Combo Vaccine Trials; Shares Up 5%	MT
09/25/09	Tranche Update on Changchun High-Tech Industry Co., Ltd.'s Equity Buyback Plan announced on November 16, 2024.	CI
01/25/01	Dual-Listing Rush Propels Hong Kong Toward Blockbuster IPO Year	MT
30/25/30	Changchun High-Tech Industry Files Hong Kong Listing Application	MT

Chart Changchun High-Tech Industry (Group) Co., Ltd.

Duration

Period

Chart Changchun High-Tech Industry (Group) Co., Ltd.

000661: Dynamic Chart

Changchun High-Tech Industry (Group) Inc. specializes in the manufacturing and marketing of biopharmaceutical products. Products include polyethylene glycol-based recombinant human growth hormone injection, recombinant human growth hormone, recombinant human follicle stimulating hormone for injection, lyophilized live varicella vaccines and rabies vaccines for human use.

Employees

11,547

Sector

Pharmaceuticals

Calendar

12/03 - Q4 2025 Earnings Release

More about the company